Welcome to our dedicated page for Picard Medical news (Ticker: PMI), a resource for investors and traders seeking the latest updates and insights on Picard Medical stock.
Picard Medical, Inc. (NYSE American: PMI) is the parent company of SynCardia Systems, LLC, a medical technology company focused on total artificial heart therapy for patients with advanced and end-stage heart failure. News about Picard Medical often centers on the SynCardia Total Artificial Heart (STAH), which company materials describe as the only commercially available total artificial heart technology for patients with end-stage heart failure and the first artificial heart approved by both the U.S. Food and Drug Administration (FDA) and Health Canada.
Readers of this PMI news page can expect coverage of clinical and technology milestones related to the SynCardia Total Artificial Heart and the next-generation, fully implantable Emperor Total Artificial Heart platform. Recent company announcements have highlighted in vitro and in vivo data on the Emperor system, including the first pre-clinical implantations of the fully implantable device, as well as presentations at specialized heart failure and mechanical circulatory support conferences.
Picard Medical’s news flow also includes updates on product enhancements, such as the rollout of FDA-cleared CPC1 Connector Covers designed to provide additional protection and comfort for patients using the SynCardia Total Artificial Heart. Corporate and capital markets developments, including senior secured debt financings, registration statements, and participation in healthcare investor conferences, are disclosed through press releases and corresponding SEC filings.
Investors and clinicians following PMI news can use this page to review company communications on regulatory developments, collaboration agreements for the Emperor platform, clinical data presentations, and broader strategic updates related to total artificial heart technology. The news archive offers a consolidated view of how Picard Medical and SynCardia are advancing their artificial heart platforms and engaging with the heart failure and medical device communities.
Picard Medical (NYSE American: PMI) announced that a patient has reached 2,900 days (over eight years) of continuous support with the SynCardia Total Artificial Heart (STAH), the longest recorded time a person has lived on an artificial heart.
The company noted the STAH is the world’s first total artificial heart approved by both the U.S. FDA and Health Canada. Picard said the milestone highlights long-term durability and reliability of the STAH and that it is developing Emperor, a next-generation fully implantable artificial heart system to expand access to long-term support worldwide.
Picard Medical (NYSE American: PMI) announced that CEO Patrick NJ Schnegelsberg will present data on the fully implantable Emperor Total Artificial Heart (TAH) at the CSI Focus D-HF conference in Frankfurt, Germany.
The conference runs December 5–6, 2025, and the presentation is scheduled for Saturday, December 6, 2025, 13:00–13:45 CET in the Red Room during the Durable Mechanical Circulatory Support session. Picard is parent of SynCardia Systems, maker of the first TAH approved by both the U.S. FDA and Health Canada.
Picard Medical (NYSE American: PMI) will present in vitro benchtop data for the fully implantable Emperor Total Artificial Heart at the 31st Annual Meeting of the International Society for Mechanical Circulatory Support (ISMCS 2025) in Vienna, Austria, Dec 1–4, 2025.
The company’s presentation is scheduled for Thursday, December 4, 2025 at 14:05 CET in Mini Oral Session 3: Hemocompatibility and Heart/Pump Interaction. Presenter: Duffy Elmer, Engineering Project Manager. The Emperor platform uses an internal motor driven design that removes the need for an external pneumatic driver and is engineered to improve patient mobility and quality of life.
Picard Medical (NYSE American: PMI) announced on November 19, 2025 that SynCardia completed the first in vivo implantations of the fully implantable Emperor Total Artificial Heart (TAH).
The Emperor TAH was implanted in three pre-clinical models, taken off bypass without issues, and provided full, stable blood circulation while operating energy-efficiently and without technical problems. Observed behaviors included stable hemodynamics, physiologic preload sensitivity, and afterload independence consistent with company laboratory goals.
SyndCardia plans additional pre-clinical studies to refine system parameters before further program acceleration.
Picard Medical (NYSE: PMI) reported third-quarter 2025 results and corporate milestones on Nov 14, 2025. The company completed its IPO on Sept 2, 2025, raising approximately $19.5M gross ($15.5M net), and used proceeds to retire convertible debt and fund R&D and commercial expansion for SynCardia Total Artificial Heart.
Q3 revenue was $1.19M (+35% YoY); gross loss narrowed 81% to $0.13M; operating loss improved to $3.36M from $3.77M. Nine-month revenue was $3.93M (+11% YoY). Net loss was $22.7M, including a $12.4M non-cash derivative revaluation tied to convertible debt conversion. Picard also received a U.S. patent for its next‑generation implantable Total Artificial Heart and added two independent directors.
Picard Medical (NYSE American: PMI) will attend the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 20, 2025 in New York City.
Patrick NJ Schnegelsberg, CEO of Picard Medical, will be available for one-on-one investor meetings; investors should contact their Canaccord Genuity sales representative to schedule a meeting with management.
Picard Medical (NYSE American: PMI) will exhibit at the American Heart Association Annual Meeting on November 7–10, 2025 in New Orleans.
The company will showcase the SynCardia Total Artificial Heart (STAH) at booth #3408, present clinical data, discuss patient eligibility and share real‑world patient experiences. CEO Patrick NJ Schnegelsberg highlighted plans to engage physicians and attendees on the device's latest developments and resources for care teams and patients.
Picard Medical (NYSE American: PMI) on October 24, 2025 said it is not aware of any undisclosed material change in its operations or financial condition that would explain recent intraday stock volatility. The company stated it remains focused on executing strategic and operational priorities and will continue to meet disclosure obligations under applicable securities laws.
Investors are directed to the company website and SEC filings for additional information.
Philip Morris International (NYSE: PM) urged the FDA advisory committee on October 7, 2025 to recommend continued marketing of IQOS as a modified risk tobacco product (MRTP). The FDA previously found evidence supporting the reduced-exposure claim for IQOS. PMI submitted renewal requests covering two device versions and three HEETS variants and highlighted global usage figures: ~34 million legal-age IQOS consumers as of June 30, 2025 and 41 million smoke-free product users globally. PMI stated its smoke-free business accounted for 41% of H1 2025 net revenues and noted ongoing FDA reviews for IQOS ILUMA (pending ~two years).
Picard Medical (NYSE American: PMI) has strengthened its intellectual property portfolio with the grant of U.S. Patent No. 12,383,722 B2 for its next-generation SynCardia Total Artificial Heart (STAH), dubbed the "Emperor." The company now holds 34 patented claims across three U.S. patents and has secured protection in China through Patent No. 115279450 B.
The Emperor represents a significant advancement as a fully implantable artificial heart that provides pulsatile flow without requiring an external pneumatic driver. This technology aims to revolutionize treatment options for end-stage heart failure patients, offering enhanced patient flexibility and improved quality of life.
FAQ
What is the current stock price of Picard Medical (PMI)?
What is the market cap of Picard Medical (PMI)?
